Trial · NCT03429803
DAY101 In Gliomas and Other Tumors
NCT03429803, Phase 1, Completed, Karen D. Wright, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. DAY101 In Gliomas and Other Tumors. Trials, record NCT03429803. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03429803
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- DAY101 In Gliomas and Other Tumors
- NCT number
- NCT03429803
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 44 participants, actual
- Lead sponsor
- Karen D. Wright, MD
- Conditions
- Low-grade Glioma
- Interventions
- DAY101
- First posted
- 2018-02-12
- Last updated
- 2026-02-19
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose Limiting Toxicity (DLT) | Greater and equal 28 days | A DLT is defined as an AE assessed as at least possibly related to the study medication, which occurs during Cycle 1 (typically 28 days following the first dose of DAY101) |
| Secondary | Blood samples for DAY101 concentration measurements (i.e. pharmacokinetic measures) | cycle 1 day 1 1-4 hours post dose; cycle 1 day 3-6 random level; cycle 2 day 1 pre-dose; cycle 3 day 1 random level; end of therapy or at time of toxicity requiring patient be taken off study or dose held; time of surgery if applicable) | measurement of phosphorylated ERK in peripheral blood mononuclear cells, will be performed on all patients in the phase I component of the trial |
| Secondary | Best Overall Response | 48 Weeks | Pediatric patients (\>1 year and \<25 years of age). each evaluable patient will be classified as either a responder (complete response, partial response, or stable disease) or a non-responder (\<stable disease) |
| Secondary | Number of participants with adverse events | 48 Weeks | Frequency of adverse events (AEs) with once weekly administration of DAY101 |
| Secondary | Number of participants with serious adverse events | 48 weeks | Frequency of serious adverse events (SAEs) with once weekly administration of DAY101 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P50CA165962 | Targeted Therapies for Glioma | BATCHELOR, TRACY T | BRIGHAM AND WOMEN'S HOSPITAL | NATIONAL CANCER INSTITUTE | 2013 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03429803
GET https://conductscience.org/api/trials/v1/NCT03429803/registered